Development and verification of an immune?related gene pairs prognostic signature in ovarian cancer

Ovarian cancer (OV) is the most common gynaecological worldwide. Immunotherapy has recently been proven to be an effective treatment strategy. The work here attempts produce a prognostic immune-related gene pair (IRGP) signature estimate OV patient survival. Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases provided genetic expression profiles clinical data of patients. Based on InnateDB database least absolute shrinkage selection operator (LASSO) regression model, we first identified 17-IRGP associated with average area under curve (AUC) values training, validation, all TCGA sets were 0.869, 0.712, 0.778, respectively. noticeably split patients into high- low-risk groups different outcomes. As suggested by functional study, some biological pathways, including Toll-like receptor chemokine signalling significantly negatively correlated risk scores; however, pathways such as p53 apoptosis had positive correlation. Moreover, tumour stage III, IV, grade G1/G2, G3/G4 samples significant differences in scores. In conclusion, was produced predict outcomes OV, providing new insights immunological biomarkers.